The etiological agent of AIDS was first identified in 1983, by the French virologist Luc Montagnier and theyidentified retroviral particles and reversetranscriptase activity in cultures of lym-phocytes isolated from AIDS patients. This was the first report associating a retrovirus with AIDS, but not conclusive on their causal relationship. Less than a year later, the group led by Robert C. Gallo at the National Cancer Institute provided solid evidences in four reports, supporting the hypothesis of a new retro-virus as the causal agent of AIDS [5] [6] [7] [8] [9] .The corner stone in Gallo-s work was to replicate the new virus in a tumor cell line of lymphoid origin (H9), provi-ding enough viral material to characterize its proteins and to develop serologic diagnosis methods to detect antibodies specific for the virus in patient's sera 10 . Consequently, the nucleotide sequences of two diffe-rent but similar viruses were elucidated, markedly different from any previously identified human retro-virus 11, 12 . This was the basis for denominating the new entity as the Human Immunodeficiency Virus (HIV) 12 .
Burden in Bangladesh:
In world,total no of people living with HIV is 36.7million,20.9 million people is receiving antiretroviral therapy,new infected HIV case is 1.8million,deaths due to AIDS is 1.0 million. 13 In Bangladesh the first HIV case was detected in 1989.HIV prevalence remains less than 0.01% among general population.Estimated people living with HIV is 11,700.In 2017,total number of new cases were 856.Reported cases for Rohinga crises from 25 th August 2017 till now is 168.In 2015,treatment was given among 4665 people living with HIV and in the last year total no of ARV receiver was 2642. 13 antiretroviral agent, zidovudine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was shown to have a positive impact on clinical progression and death 14 The challenges of early NRTI regimens included high pill burdens, inconvenient dosing, treatment-limiting toxicities and incomplete virological suppression. Sequential monotherapy and incomplete virological suppression resulted in the emergence of multiple resistance mutations, with long-term treatment consequences.In treatment of Human immunodeficiency virus (HIV) protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), introduced in the mid-1990s, revolutionized the management of HIV infection. Highly active antiretroviral therapy (HAART) regimens, consisting of two NRTIs plus a PI or NNRTI, were capable of virological suppression (<400 copies ml"1), and widespread uptake quickly led to dramatic reductions in morbidity and mortality in the developed world 15 . HAART provides effective treatment options for treatment-naive and treatmentexperienced patients. 
Protease Inhibitor:
Regulation of HIV protease is of high importance for the correct assembly and production ofHIV. Protease inhibitors effectively block the functioning of protease enzymes in acutely andchronically HIV-infected CD4 cells. Inhibition of HIV protease enzymes results in the liberationof immature and noninfectious viral particles 18 . Examples of this group of drugs includelopinavir/ritonavir, Indinavir, Ritonavir, Nelfinavir, and Amprenavir.
Fusion Inhibitors :
This class of drugs acts by blocking HIV from entering the CD4 cells of infected patients. Theyinhibit the fusion of HIV particles with the CD4 cells 19 . Enfuvirtide is an example of a fusion inhibitor used in HIV treatment.
Chemokine Receptor 5 Antagonist
This group of drugs prevents the infection by blocking the Chemokine Receptor 5 (CCR5)antagonist receptor present on CD4 cells. In the absence of vacant CCR5 receptors, HIV fails to gain entry and infect the cell 20 . Maraviroc is an example of a CCR5 antagonist used in HIV treatment.
Integrase Strand Transfer Inhibitors
Strand transfer inhibitors prevent the integration of viral DNA into the host genome of CD4 cells by an integrase enzyme. Blocking integrase prevents HIV from replicating 21 . Raltegravir, Elvitegravir, and Dolutegravir are some medications in this category.
ART should be initiated in all individuals with HIV regardless of WHO clinical stage or CD4 count.Adherence to treatment is of paramount importance in order to achieve the full efficacy of treatment and also to prevent the incidence of drug resistance 23 .
The strategy of using two NRTIs plus a potent third agent still forms the cornerstone of current treatment principles, and is now referred to as combination antiretroviral therapy. According to WHO Guideline there are first, second, and third line treatment options 22 . Pediatric patients: Patients below three years of age should be given Lopinavir/Ritonavir(LPV/r)-based treatment, even under NNRTI exposure. When LPV/r is not a viable option, NVP based treatment should be used. For infected children who are over age three, EFV is the ideal NNRTI while NVP has been identified as the second option. For infected children younger than three years of age, who develop TB while on the Lopinavir/Ritonavir (LPV/r)-based treatment, the NRTI regimen should be switched to Abacavir (ABC) + 3TC or AZT + 3TC until the TB infection is cleared. NRTI regimens similar to that of adults (TDF + 3TC (or FTC)) or (AZT +3TC) or (ABC + 3TC) are preferred for patients between 10 and 19 years of age who weight 35 kg or more.
First-line ART

Second-line ART
Adults: including pregnant and breastfeeding patients: When a first-line treatment of ART fails,a second-line ART should be utilized. The second-line ART is comprised primarily of two NRTIs and a ritonavirboosted PI. The recommended option for second-line ART includes AZT and 3TC as the NRTI. After the failure of AZT or stavudine (d4T) + 3TC-based firstline regimen,TDF + 3TC (or FTC) as the NRTI should be considered. When first-line NNRTI-based treatment fails, two NRTIs + a boosted PI are suggested.
Pediatric patients: For children below three years of age, first-line ART is continued even whenit fails. No change in treatment is recommended; instead, adequate steps should be taken to improve adherence to the ART regimen. If first-line ART fails in children ages three and up, a second-line treatment consisting of one NNRTI and two NRTIs should be given. If ABC or TDF +3TC (or FTC) fails, the recommended option is AZT + 3TC. After a failure of AZT or d4T + 3TC(or FTC) in first-line treatment, the preferred NRTI option is ABC or TDF + 3TC (or FTC).
Third-line ART
If first-and second-line ART fails, the WHO recommends inclusion of new medicines with the least amount of risk for development of cross-resistance towards previously used drugs (e.g. integrase inhibitors and second-generation NNRTIs and PIs).
Factors to consider when selecting ART
The major factors that deserve thorough consideration while choosing an ART for a patient include the viral load and CD4 cell count before the treatment, the result of HIV genotypic drug resistance test, HLA-B*5701 status, patient preferences, and anticipated adherence. Comorbid conditions to screen prior to ART include cardiovascular disease, hyperlipidemia, renal disease,osteoporosis, psychiatric illness, neurologic disease, drug abuse or dependency requiring narcotic replacement therapy, pregnancy, coinfections with hepatitis C (HCV), hepatitis B (HBV), and tuberculosis (TB) 24 .
Contraindications should also be considered: 1. Creatinine clearance is less than 50 ml per minute:
Tenofovir.
Patients on psychoactive drug treatment:
Efavirenz.
3. Patients who are pregnant or who are trying to conceive: Efavirenz.
4. ALT elevation: Nevirapine.
CD4 count monitoring for therapeutic response
Monitoring patients' viral load is critical to identify ART response. When the viral load analysis is not practical via polymerase chain reaction (PCR), branched chained DNA (bDNA), and nucleic acid sequence-based amplification (NASBA), the CD4 count is used as an indicator of HIV treatment response. During the first year of treatment, increases in CD4 count from 50 to 150 cells/mm3 with an increased response in the first trimester are considered as a positive response. CD4 count rises steadily ranging from 50 to 100 cells/mm3 per year until equilibrium is reached in the subsequent years (normal range: 500 cells/mm3 to 1200 cells/mm3) 25 . Periodic monitoring of CD4 count is required during and even after the patient achieves normal CD4 count under ART.
A number of treatment independent factors like age, viral load, genetic make-up, lifestyle, quality of health care, etc., negatively influence the CD4 counts and HIV disease progression. Under such circumstances, a change in ART medication might be required.
Treatment available in Bangladesh:
In givers, guardians and family members on nutritional requirements, hygiene, positive living and also on measures to prevent further transmission of infection 6) Refer patients requiring specialized services (including admission) to other departments or higher facilities 7) Provide comprehensive package of services including condoms and prevention education with a view towards "Positive Prevention" 8) Ultimately integrating HIV care into general health system for long term sustainability. 26 .
The regimen that are available in ART centre are: 
Conclusion:
People living with HIV in Bangladesh are getting antiretroviral drugs and all facilities are available for diagnosing,treating and monitoring treatment. 
